JP2023529011A5 - - Google Patents

Info

Publication number
JP2023529011A5
JP2023529011A5 JP2022576471A JP2022576471A JP2023529011A5 JP 2023529011 A5 JP2023529011 A5 JP 2023529011A5 JP 2022576471 A JP2022576471 A JP 2022576471A JP 2022576471 A JP2022576471 A JP 2022576471A JP 2023529011 A5 JP2023529011 A5 JP 2023529011A5
Authority
JP
Japan
Prior art keywords
methyl
inden
methylidene
phenyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529011A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/099626 external-priority patent/WO2021249529A1/en
Publication of JP2023529011A publication Critical patent/JP2023529011A/ja
Publication of JP2023529011A5 publication Critical patent/JP2023529011A5/ja
Priority to JP2026048292A priority Critical patent/JP2026122957A/ja
Pending legal-status Critical Current

Links

JP2022576471A 2020-06-12 2021-06-11 インデン化合物、その医薬組成物、及びそれらの治療応用 Pending JP2023529011A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026048292A JP2026122957A (ja) 2020-06-12 2026-03-24 インデン化合物、その医薬組成物、及びそれらの治療応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038737P 2020-06-12 2020-06-12
US63/038,737 2020-06-12
PCT/CN2021/099626 WO2021249529A1 (en) 2020-06-12 2021-06-11 Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026048292A Division JP2026122957A (ja) 2020-06-12 2026-03-24 インデン化合物、その医薬組成物、及びそれらの治療応用

Publications (2)

Publication Number Publication Date
JP2023529011A JP2023529011A (ja) 2023-07-06
JP2023529011A5 true JP2023529011A5 (enExample) 2024-09-24

Family

ID=78846886

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022576471A Pending JP2023529011A (ja) 2020-06-12 2021-06-11 インデン化合物、その医薬組成物、及びそれらの治療応用
JP2026048292A Pending JP2026122957A (ja) 2020-06-12 2026-03-24 インデン化合物、その医薬組成物、及びそれらの治療応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026048292A Pending JP2026122957A (ja) 2020-06-12 2026-03-24 インデン化合物、その医薬組成物、及びそれらの治療応用

Country Status (10)

Country Link
US (1) US12649712B2 (enExample)
EP (1) EP4165009A4 (enExample)
JP (2) JP2023529011A (enExample)
KR (1) KR20230024976A (enExample)
CN (1) CN116472034B (enExample)
AU (1) AU2021287932B2 (enExample)
CA (1) CA3182036A1 (enExample)
IL (1) IL298984A (enExample)
TW (1) TW202214555A (enExample)
WO (1) WO2021249529A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4337628A4 (en) * 2021-05-15 2025-08-27 Nucmito Pharmaceuticals Company Ltd INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS BASED THEREON AND THEIR THERAPEUTIC APPLICATIONS
EP4619369A1 (en) * 2022-11-16 2025-09-24 Nucmito Pharmaceuticals Co., Ltd. Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
CN116589404B (zh) * 2023-04-24 2026-05-15 华南理工大学 一种靶向β淀粉样蛋白的光敏剂及其制备方法与应用
WO2025051192A1 (en) * 2023-09-06 2025-03-13 Nucmito Pharmaceuticals Company Limited Rxr-alpha modulators for treating malignancy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
DE10163426A1 (de) * 2001-12-21 2003-07-03 Max Planck Gesellschaft Pharmakologisch wirksame Inden-Derivate
DK2250161T3 (da) * 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
KR101889290B1 (ko) * 2010-05-06 2018-08-20 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 레티노이드 수용체-선택적 경로와 관련된 방법 및 조성물
US20200237710A1 (en) 2019-01-25 2020-07-30 Alfred Ordman Synergistic composition of vitamin c and vitamin k1, and compositions thereof for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2019077725A5 (enExample)
EA030430B1 (ru) Композиции и способы модуляции фарнезоидных х-рецепторов
EP3682881B1 (en) Compound having cyclic structure
CN108473426B (zh) 环状胺衍生物和其医药用途
EA035256B1 (ru) Ингибиторы аутотаксинов, содержащие гетероарил-бензил-амидное ядро
JP2009507011A5 (enExample)
TW200808788A (en) Azolecarboxamide derivative
JP2022546717A (ja) Ｕｓｐ３０阻害剤としての活性を有する置換シアノピロリジン類
US20150274653A1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP2010518026A5 (enExample)
RU2005131165A (ru) Производные имидазол-4-илэтинилпиридина
JP2019532052A5 (enExample)
TW201245144A (en) Novel compounds useful for the treatment of metabolic and inflammatory diseases
JP7854780B2 (ja) 核内受容体に対して活性の化合物
JP2006510609A5 (enExample)
JP2012508274A5 (enExample)
JP2024500377A5 (enExample)
NZ552501A (en) Novel cyclic aminobenzoic acid derivative
JP2017537937A (ja) 線維症の小分子阻害剤
JP2010504321A5 (enExample)
US20050009785A1 (en) Heterocyclic compounds
US9242971B2 (en) Compounds for the treatment of conditions associated with DGAT1 activity
RU2010151475A (ru) Ингибиторы jnk
US20210395202A1 (en) Orally available seh/pde4 dual inhibitors
AU2018321287A1 (en) Azole analogues and methods of use thereof